Pharma Triples Price Of Potential Anti-COVID Drug

Axios reports:

This month, Jaguar Health more than tripled the price of its lone FDA-approved drug, right after asking the federal government to expand the use of its drug to coronavirus patients. Jaguar Health drastically raised the price of a drug during the height of the pandemic, but executives argued the move was needed to stave off the company’s collapse.

Going into this year, the list price of a 60-pill bottle of Mytesi — an antidiarrheal medication specifically for people with HIV/AIDS who are on antiretroviral drugs — was $668.52. On April 9, Jaguar Health raised the price to $2,206.52, according to pricing data from Elsevier’s Gold Standard Drug Database.

The price hike coincides with the company’s push to get its drug to more patients — specifically those diagnosed with COVID-19.

Read the full article.